RedHill Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.29	-	-	61.8	85.76
Revenue Growth	-	-	-	-27.94%	33.25%
Cost of Revenue	-	-	-	33.34	49.41
Gross Profit	0.29	-	-	28.46	36.35
Selling, General & Admin	6.17	4.89	6.02	64.03	87.99
Research & Development	2.02	1.59	3.53	7.28	29.5
Operating Expenses	8.2	6.48	9.55	71.31	117.49
Operating Income	-7.91	-6.48	-9.55	-42.84	-81.14
Interest Expense	-0.02	-0.04	-0.06	-41.33	-16.57
Interest & Investment Income	0.02	0.08	0.09	0.14	0.05
Earnings From Equity Investments	-0.03	-	-	-	-
Currency Exchange Gain (Loss)	-0.09	0.03	-0.12	-0.04	-0.03
Other Non Operating Income (Expenses)	-0.06	6.77	-7.4	12.41	-0.07
EBT Excluding Unusual Items	-8.08	0.36	-17.04	-71.67	-97.74
Other Unusual Items	-	-	-1.46	-	-
Pretax Income	-8.08	0.36	-18.5	-71.67	-97.74
Earnings From Continuing Operations	-8.08	0.36	-18.5	-71.67	-97.74
Earnings From Discontinued Operations	7.65	-8.63	42.41	-	-
Net Income	-0.43	-8.27	23.92	-71.67	-97.74
Net Income to Common	-0.43	-8.27	23.92	-71.67	-97.74
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	3	1	0	0	0
Shares Outstanding (Diluted)	3	1	0	0	0
Shares Change	156.37%	375.56%	320.45%	32.46%	27.72%
EPS (Basic)	-0.14	-6.71	92.30	-1162.89	-2100.80
EPS (Diluted)	-0.14	-6.71	92.30	-1162.89	-2100.80
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-7.2	-8.94	-16.83	-29.38	-65.16
Free Cash Flow Per Share	-2.28	-7.26	-64.96	-476.76	-1400.52
Gross Margin	100.00%	-	-	46.06%	42.39%
Operating Margin	-2765.38%	-	-	-69.33%	-94.61%
Profit Margin	-150.00%	-	-	-115.97%	-113.98%
Free Cash Flow Margin	-2516.08%	-	-	-47.55%	-75.98%
EBITDA	-7.79	-6.38	-7.56	-34.69	-62.99
EBITDA Margin	-	-	-	-56.13%	-73.45%
D&A For EBITDA	0.12	0.1	1.99	8.15	18.15
EBIT	-7.91	-6.48	-9.55	-42.84	-81.14
EBIT Margin	-	-	-	-69.33%	-94.61%

SEC Filings: 10-K · 10-Q